scholarly journals Lifestyle Aspects As A Predictor Of Pain Among Oldest-Old Primary Care Patients – A Longitudinal Cohort Study

2019 ◽  
Vol Volume 14 ◽  
pp. 1881-1888
Author(s):  
Tina Mallon ◽  
Marion Eisele ◽  
Hans-Helmut König ◽  
Christian Brettschneider ◽  
Susanne Roehr ◽  
...  
BMJ ◽  
2009 ◽  
Vol 338 (feb02 1) ◽  
pp. a3079-a3079 ◽  
Author(s):  
E Licht-Strunk ◽  
H W J Van Marwijk ◽  
T Hoekstra ◽  
J W R Twisk ◽  
M De Haan ◽  
...  

BMJ Open ◽  
2019 ◽  
Vol 9 (12) ◽  
pp. e033545 ◽  
Author(s):  
Kristjan Linnet ◽  
Johann Agust Sigurdsson ◽  
Margret Olafia Tomasdottir ◽  
Emil Larus Sigurdsson ◽  
Larus Steinthor Gudmundsson

ObjectivesTo assess the risk of mortality in primary care patients, multimorbid (≥2 chronic conditions) or not, prescribed hypnotics/anxiolytics.DesignA longitudinal cohort studySettingPrimary healthcare in the Reykjavik area.Participants114 084 individuals (aged 10–79 years, average 38.5, SD 18.4) contacting general practitioners during 2009–2012 (mortality follow-up to 31 December 2016). Of those, the reference group comprised 58 560 persons who were neither multimorbid nor had redeemed prescriptions for hypnotics/anxiolytics. Participants (16 108) redeeming prescriptions for hypnotics/anxiolytics on a regular basis for 3 consecutive years were considered as consistent, long-term users. They were subdivided into low-dose (1–300 defined daily doses (DDD)/3 years), medium-dose (301–1095 DDDs/3 years) and high-dose users (>1095 DDDs/3 years). All six groups taking these drugs were compared with the reference group.Main outcome measuresAll-cause mortality.ResultsHRs were calculated with the no multimorbidity—no drug group as a reference, using Cox proportional hazards regression model adjusting for age, sex and the number of chronic conditions (n=111 767), patients with cancer excluded. During follow-up, 516 358 person-years in total, 1926 persons died. Mean follow-up was 1685 days (4.6 years), range 1–1826 days (5.0 years). For all multimorbid patients who took no drugs the HR was 1.14 (95% CI 1.00 to 1.30) compared with those without multimorbidity. HRs in the non-multimorbid participants varied from 1.49 to 3.35 (95% CI ranging from 1.03 to 4.11) with increasing doses of hypnotics/anxiolytics, and correspondingly from 1.55 to 3.52 (1.18 to 4.29) in multimorbid patients.ConclusionsMortality increased in a dose-dependent manner among both multimorbid and non-multimorbid patients taking hypnotics/anxiolytics. This increase was clearly associated with prescribing of these drugs. Their use should be limited to the recommended period of 2–4 up to 6 weeks; long-term use may incur increased risk and should be re-examined.


2018 ◽  
Vol 101 (1) ◽  
pp. 105-112 ◽  
Author(s):  
Jane Gunn ◽  
Jacqui Cameron ◽  
Konstancja Densley ◽  
Sandra Davidson ◽  
Susie Fletcher ◽  
...  

2018 ◽  
Vol 36 (1) ◽  
pp. 12-20 ◽  
Author(s):  
Floor Holvast ◽  
Richard C Oude Voshaar ◽  
Hans Wouters ◽  
Karin Hek ◽  
Francois Schellevis ◽  
...  

2010 ◽  
Vol 10 (1) ◽  
Author(s):  
Yasumichi Arai ◽  
Toshimitsu Iinuma ◽  
Michiyo Takayama ◽  
Midori Takayama ◽  
Yukiko Abe ◽  
...  

2013 ◽  
Vol 63 (612) ◽  
pp. e499-e505 ◽  
Author(s):  
Jamie Parmenter ◽  
Caroline Mitchell ◽  
Jenny Keen ◽  
Phillip Oliver ◽  
Georgina Rowse ◽  
...  

2019 ◽  
Vol 3 (1) ◽  
pp. e17-e25 ◽  
Author(s):  
John S Ji ◽  
Anna Zhu ◽  
Chen Bai ◽  
Chih-Da Wu ◽  
Lijing Yan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document